CPC
TAK icon

Consolidated Planning Corp’s Takeda Pharmaceutical TAK Stock Holding History

Consolidated Planning Corp’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2
Closed – – 395
2021
Q3 		$0 Buy
+2
New +$34 ﹤0.01% 487

Other funds holding TAK

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Consolidated Planning Corp's TAK Position: Q4 2021 in Review

Consolidated Planning Corp sold out of Takeda Pharmaceutical (TAK) in Q4 2021, closing a stake of 2 shares.

Consolidated Planning Corp first reported a position in TAK in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 298 funds tracked by Wall St. Rank hold TAK as of Q4 2021.

  • Consolidated Planning Corp reported no remaining Takeda Pharmaceutical position as of Q4 2021 after selling out during the quarter.
  • Consolidated Planning Corp sold 2 Takeda Pharmaceutical shares in Q4 2021.
  • Consolidated Planning Corp first reported a position in Takeda Pharmaceutical in Q3 2021 and held it in 1 quarter.
  • Consolidated Planning Corp's Takeda Pharmaceutical position peaked at $0 in Q3 2021.
  • 298 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2021.

Based on Consolidated Planning Corp's 13F filing for Q4 2021, filed 11 Feb 2022.